Modulation of cisplatin sensitivity in human ovarian carcinoma A2780 and SKOV3 cell lines by sulforaphane
| Autor: | Paulina Gronesova, Luba Hunakova, Duraj J, Dana Cholujova, Jan Sedlak, Ivan Chalupa, Eva Horváthová |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
endocrine system medicine.medical_specialty endocrine system diseases DNA damage NF-E2-Related Factor 2 Antineoplastic Agents Apoptosis Biology Toxicology chemistry.chemical_compound Isothiocyanates Internal medicine Ovarian carcinoma Cell Line Tumor Antineoplastic Combined Chemotherapy Protocols medicine Humans MTT assay Cisplatin Ovarian Neoplasms General Medicine medicine.disease female genital diseases and pregnancy complications Gene Expression Regulation Neoplastic chemistry Drug Resistance Neoplasm Sulfoxides Cancer research Female Comet Assay Ovarian cancer Antagonism Sulforaphane medicine.drug DNA Damage Signal Transduction |
| Zdroj: | Toxicology letters. 230(3) |
| ISSN: | 1879-3169 |
| Popis: | Cisplatin resistance is one of the major obstacles in the treatment of ovarian cancer. In an effort to look for new possibilities of how to overcome this difficulty, we studied the mechanisms of the interactions between sulforaphane (SFN) and cisplatin (cisPt) in combined treatment of human ovarian carcinoma A2780 and SKOV3 cell lines. Synergy (A2780) and antagonism (SKOV3) found in MTT assay was confirmed by apoptosis. While SFN significantly potentiated cisPt-induced DNA damage in A2780 cells, it protected SKOV3 cells against cisPt-crosslinking. We revealed a less efficient Nrf-2 pathway inducibility by SFN in A2780 compared to SKOV3 cells, when activation of the Nrf-2 pathway incites its protectivity against cisPt. Thus, different activation of the Nrf-2 pathway may explain the dual effects of SFN. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect